Misplaced Pages

6-Fluoro-AMT

Clinical data
Other names	6-Fluoro-AMT; 6-Fluoro-αMT; 6F-AMT; 6F-αMT; 6-F-AMT; 6-F-αMT
Identifiers
IUPAC name 1-(6-fluoro-1H-indol-3-yl)propan-2-amine
CAS Number	712-11-8
PubChem CID	15289992
ChemSpider	14228507
CompTox Dashboard (EPA)	DTXSID701045426
Chemical and physical data
Formula	C11H13FN2
Molar mass	192.237 g·mol
3D model (JSmol)	Interactive image
SMILES NC(C)CC1=CNC2=CC(F)=CC=C21
InChI InChI=1S/C11H13FN2/c1-7(13)4-8-6-14-11-5-9(12)2-3-10(8)11/h2-3,5-7,14H,4,13H2,1H3 Key:XYJYWUUXCUJXAI-UHFFFAOYSA-N

6-Fluoro-α-methyltryptamine (6-fluoro-AMT, 6F-AMT) is a tryptamine derivative related to compounds such as α-methyltryptamine (AMT) and 5-MeO-AMT which has been sold as a designer drug.

Animal tests showed the drug to be somewhat less potent in terms of pharmacological activity than AMT or 5-fluoro-AMT. It produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents. Its IC₅₀Tooltip half-maximal inhibitory concentration for monoamine oxidase A (MAO-A) inhibition is 580 to 1,800 nM, compared to 180 to 450 nM for 5-fluoro-AMT and 380 nM for AMT.

6-Fluoro-AMT was allegedly manufactured and sold from the laboratory operated by Leonard Pickard and Gordon Todd Skinner, who described 6-fluoro-AMT as "a beast". In interviews, Skinner stated that he first began to experiment with 6-fluoro-AMT in the early 1980s by giving it to high school friends. Their experiences made him cautious about the appropriate doses, which he said ranged from 25 to 75 mg (Skinner weighed about 250 lbs at the time of his own bioassay). Skinner said that 6-fluoro-AMT is a long-lasting psychedelic with more time distortion and that it was enhanced by combination with ALD-52.

See also

• 5-Fluoro-AET
• 5-Fluoro-AMT
• 6-Fluoro-DMT
• 6-Fluoro-DET
• 7-Chloro-AMT
• O-4310

References

1. ^ Morris H (2010). "Life is a Cosmic Giggle on the Breath of the Universe. A Tour of Gordon Todd Skinner's Subterranean LSD Palace". Vice Magazine. Archived from the original on 2014-10-13. Retrieved 2017-08-23.
2. ^ "Unusual Analogues: Drugs Used by Gordon Todd Skinner". thislandpress.com. This Land Press. Retrieved 8 April 2016.
3. Kalir A, Szara S (November 1963). "Synthesis and Pharmacological Activity of Fluorinated Tryptamine Derivatives". Journal of Medicinal Chemistry. 6 (6): 716–719. doi:10.1021/jm00342a019. PMID 14184932.
4. Halberstadt AL, Geyer MA (2018). "Effect of Hallucinogens on Unconditioned Behavior". Curr Top Behav Neurosci. 36: 159–199. doi:10.1007/7854_2016_466. PMC 5787039. PMID 28224459.
5. ^ Nakagawasai O, Arai Y, Satoh SE, Satoh N, Neda M, Hozumi M, Oka R, Hiraga H, Tadano T (January 2004). "Monoamine oxidase and head-twitch response in mice. Mechanisms of alpha-methylated substrate derivatives". Neurotoxicology. 25 (1–2): 223–232. doi:10.1016/S0161-813X(03)00101-3. PMID 14697897.
6. Tadano T, Neda M, Hozumi M, Yonezawa A, Arai Y, Fujita T, Kinemuchi H, Kisara K (February 1995). "alpha-Methylated tryptamine derivatives induce a 5-HT receptor-mediated head-twitch response in mice". Neuropharmacology. 34 (2): 229–234. doi:10.1016/0028-3908(94)00119-d. PMID 7617148.
7. Wagmann L, Brandt SD, Kavanagh PV, Maurer HH, Meyer MR (April 2017). "In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks". Toxicol Lett. 272: 84–93. doi:10.1016/j.toxlet.2017.03.007. PMID 28302559.
8. "Advantageous tryptamine compositions for mental disorders or enhancement". Google Patents. 20 September 2021. Retrieved 8 December 2024.

This psychoactive drug-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• 5-HT2A agonists
• Alpha-Alkyltryptamines
• Fluoroarenes
• Monoamine oxidase inhibitors
• Psychedelic tryptamines
• Serotonin receptor agonists
• Psychoactive drug stubs